Rational combination of the IGF-1R/IR tyrosine kinase inhibitor (TKI), OSI-906, with the MEK inhibitor, U0126, results in synergistic and apoptotic effects in human colorectal cancer (CRC) cell lines

被引：0
|
作者：
Flanigan, Sara A.
Pitts, Todd M.
Kulikowski, Gillian N.
Tan, Aik Choon
Nallapareddy, Sujatha
Tentler, John J.
Eckhardt, S. Gail
Leong, Stephen
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163JARG-09-A256
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A256
引用
收藏
页数：3
相关论文
共 26 条
  • [1] Identification of candidate microRNAs that correlate with sensitivity to the IGF-1R/IR inhibitor, OSI-906, in colorectal cancer (CRC) cell lines
    Tan, Aik Choon
    Tentler, John J.
    Ryugazova, Nadezdah
    Kachaeva, Maria I.
    Pitts, Todd M.
    Eckhardt, S. Gail
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [2] OSI-906: A DUAL IGF-1R/IR INHIBITOR FOR THE TREATMENT OF CANCER
    Buck, E.
    Gokhale, P.
    Lerner, L.
    Wild, R.
    Pachter, J.
    Epstein, D.
    Miglarese, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 9 - 10
  • [3] Development and validation of an integrated genomic classifier to predict sensitivity to the IGF-1R/IR tyrosine kinase inhibitor, OSI-906, in colorectal cancer
    Pitts, Todd M.
    Tan, Aik Choon
    Kulikowski, Gillian N.
    Tentler, John J.
    Flanigan, Sara A.
    Leong, Stephen
    Brown, Amy
    Coldren, Chris D.
    Varella-Garcia, Marileila
    Hirsch, Fred R.
    Eckhardt, S. Gail
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [4] A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer
    Johanna C. Bendell
    Suzanne F. Jones
    Lowell Hart
    David R. Spigel
    Cassie M. Lane
    Chris Earwood
    Jeffrey R. Infante
    John Barton
    Howard A. Burris
    Investigational New Drugs, 2015, 33 : 187 - 193
  • [5] A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer
    Bendell, Johanna C.
    Jones, Suzanne F.
    Hart, Lowell
    Spigel, David R.
    Lane, Cassie M.
    Earwood, Chris
    Infante, Jeffrey R.
    Barton, John
    Burris, Howard A.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) : 187 - 193
  • [6] Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines
    Fuentes-Baile, Maria
    Ventero, Maria P.
    Encinar, Jose A.
    Garcia-Morales, Pilar
    Poveda-Deltell, Maria
    Perez-Valenciano, Elizabeth
    Barbera, Victor M.
    Gallego-Plazas, Javier
    Rodriguez-Lescure, Alvaro
    Martin-Nieto, Jose
    Saceda, Miguel
    CANCERS, 2020, 12 (12) : 1 - 18
  • [7] Combination treatment of a dual IGF-1R/IR kinase inhibitor, OSI-906, with EGFR inhibitor erlotinib in models of non-small cell lung cancer with an EGFR activating mutation
    Brown, Eric
    Chau, Andrew
    Iwata, Kenneth
    Epstein, David
    Miglarese, Mark
    Rosenfeld-Franklin, Maryland
    Thomson, Stuart
    CANCER RESEARCH, 2011, 71
  • [8] Differential effects of IGF-1R inhibitors BMS-754807 and OSI-906 in human cancer cell lines
    Saceda, M.
    Poveda-Deltell, M.
    Fuentes-Baile, M.
    Martinez-Lacaci, I.
    Gomez-Martinez, A.
    Castroviejo, N.
    Encinar-Hidalgo, J. A.
    Garcia-Morales, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S49 - S50
  • [9] Epithelial-Mesenchymal Transition Predicts Sensitivity to the Dual IGF-1R/IR Inhibitor OSI-906 in Hepatocellular Carcinoma Cell Lines
    Zhao, Hui
    Desai, Vidhi
    Wang, Jian
    Epstein, David M.
    Miglarese, Mark
    Buck, Elizabeth
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (02) : 503 - 513
  • [10] Combination treatment strategy of an IGF-1R kinase inhibitor, OSI-906 in models of progressive disease following initial respose to EGFR tyrosine kinase inhibition therapy
    Brown, Eric
    Silva, Stacia
    Pirritt, Caroline
    Wolf, Julie
    Epstein, David
    Wild, Robert
    Rosenfeld-Franklin, Maryland
    CANCER RESEARCH, 2009, 69
123